Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JRF101 + Radiation is a combination therapeutic regimen under preclinical development by Shenzhen Jinruijiye Biotechnology for the treatment of various solid tumors. The pharmacological component, JRF101, is a small molecule inhibitor of Forkhead Box M1 (FOXM1), a transcription factor that plays a critical role in cell cycle progression, DNA damage repair, and tumorigenesis. By inhibiting FOXM1, JRF101 is intended to act as a radiosensitizer, enhancing the cytotoxic effects of ionizing radiation on cancer cells and potentially mitigating mechanisms of radioresistance. The drug component has been described as utilizing a liposomal formulation to optimize delivery and pharmacokinetic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JRF101 + radiation.